(Q42223844)

English

Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Onc

scientific article published on 14 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 October 2017

Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Onc (English)

1 reference

Europe PubMed Central

18 October 2017

infectious disease

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Oliver A Cornely

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

J J Vehreschild

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

A Böhme

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

C Kahl

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

M Karthaus

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

K-A Kreuzer

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

G Maschmeyer

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

S Mousset

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

V Ossendorf

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

O Penack

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

M J G T Vehreschild

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Infectious Diseases Working Party of the Society for Haematology and Medical Oncology

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

14 March 2014

1 reference

Europe PubMed Central

18 October 2017

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1709-1718

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Infection in cancer patients. A continuing association

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after chemotherapy in patients with non-Hodgkin's lymphoma; a placebo-controlled double blind phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Dose-intensive chemotherapy in extensive-stage small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaem

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU035

21 January 2018

Identifiers

10.1093/ANNONC/MDU035

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24631945%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42223844&oldid=1566643421"